Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

While this exclusion did not change the tolvaptan-mediated decrease in TKV growth rate (Figure 1 A), there was a nonsignificant trend of increased treatment effect on the rate of eGFR decline (treatment effect 30.6% after exclusion of LR versus 27.1%).

also in 5,406 other papers